Magnesium and Ototoxicity: Hearing Protection Evidence

Magnesium and ototoxicity is a clinically important question because certain medicines and exposures can injure the cochlea or auditory nerve, sometimes permanently. Ototoxicity is most often discussed with drugs such as aminoglycoside antibiotics, platinum chemotherapy, loop diuretics, and high-dose salicylates, but the evidence supplied for this article does not include a human trial testing magnesium as a hearing-protection treatment. The responsible conclusion is therefore narrower: magnesium has biologically plausible roles in cellular excitability, oxidative stress regulation, and vascular function, yet direct clinical evidence for preventing medication-related hearing damage remains insufficient.

Magnesium and Ototoxicity: What the Current Research Landscape Actually Shows

The current evidence base does not establish magnesium as a proven preventive treatment for ototoxic hearing loss. None of the available references is a randomized trial in people receiving ototoxic medication, none measures audiograms before and after chemotherapy or aminoglycoside exposure, and none reports cochlear biomarkers such as distortion-product otoacoustic emissions, auditory brainstem response thresholds, or speech-in-noise outcomes. That distinction matters because a plausible nutrient mechanism is not the same as demonstrated hearing protection.

The available human studies instead address broader magnesium-related outcomes: insomnia, anxiety or stress, depression, and the consequences of low magnesium status. Abbasi et al. (2012) conducted a double-blind, placebo-controlled trial in 46 older adults with primary insomnia, using 500 mg/day of magnesium for eight weeks. The trial reported improvements in subjective insomnia measures and sleep-related outcomes, but it did not assess hearing, tinnitus, medication toxicity, or cochlear function.

Tarleton et al. (2017) studied 126 adults with mild-to-moderate depression in an open-label randomized crossover trial. Participants used 248 mg/day of elemental magnesium as magnesium chloride for six weeks, and the study reported a mean PHQ-9 depression-score reduction of 6.0 points during magnesium treatment compared with a 2.6-point reduction during control periods. This is clinically relevant evidence that magnesium supplementation can affect symptoms in a defined population, but it cannot be extrapolated to protection from cisplatin, gentamicin, or other ototoxic exposures.

Boyle et al. (2017) reviewed 18 studies of magnesium supplementation for subjective anxiety and stress. Their conclusion was cautious: several studies suggested possible benefit, particularly in people vulnerable to low magnesium intake or stress, but study quality and design heterogeneity limited certainty. For magnesium in ototoxicity prevention, the gap is larger still: the supplied evidence is indirect rather than disease-specific.

In practical terms, magnesium should be viewed as a nutrient with established physiological functions and incomplete clinical evidence for ear protection. A patient facing an ototoxic medication should not substitute magnesium for standard monitoring, medication review, renal-dose adjustment, baseline hearing assessment, or an audiology referral. These interventions address the exposure itself; magnesium supplementation, if appropriate, addresses nutritional status.

How Magnesium and Ototoxicity May Be Connected at the Cellular Level

Magnesium is an essential intracellular cation that helps regulate ion transport, energy metabolism, and excitatory signaling. These functions are relevant to the inner ear because cochlear hair cells and auditory neurons depend on tightly controlled electrochemical gradients. However, relevance at the molecular level is preclinical plausibility, not proof of clinical otoprotection.

Magnesium participates in more than 300 enzyme-dependent reactions and is required for ATP to function effectively in cells. Gröber et al. (2015) describes magnesium’s broad roles in neuromuscular function, glucose metabolism, cardiovascular physiology, and electrolyte balance. In a cochlear context, cellular energy demand is high: hair cells must maintain ion gradients while translating mechanical sound vibrations into neural signals. A nutrient deficiency that impairs normal cellular homeostasis could theoretically make metabolically demanding tissues less resilient, but the supplied references do not test that hypothesis in human hearing outcomes.

One proposed connection between magnesium and ototoxicity involves excitotoxicity. Magnesium normally acts as a physiological regulator of the N-methyl-D-aspartate (NMDA) receptor channel, influencing calcium entry during excitatory neurotransmission. Excessive intracellular calcium can activate damaging enzymatic pathways, increase mitochondrial strain, and promote reactive oxygen species formation. That mechanism is scientifically coherent, yet no study in the provided list demonstrates that magnesium supplementation prevents these processes in the human cochlea during medication exposure.

Oxidative injury is another reasonable area of interest. Many forms of ototoxic damage are thought to involve reactive oxygen species, lipid peroxidation, mitochondrial dysfunction, inflammation, or impaired blood flow within the stria vascularis and cochlear microcirculation. Magnesium status may influence endothelial function and inflammatory signaling, as discussed broadly by DiNicolantonio et al. (2018) and Gröber et al. (2015). Still, neither review provides direct evidence that oral magnesium preserves hearing thresholds in patients receiving ototoxic drugs.

The distinction between magnesium status and supplementation is also important. Serum magnesium is tightly regulated and may remain within a reference interval despite lower intracellular or total-body magnesium stores. DiNicolantonio et al. (2018) argues that subclinical magnesium deficiency may be underrecognized because serum measurements are an imperfect proxy for whole-body status. That concern may justify a clinician’s attention to nutrition in patients with poor intake, gastrointestinal loss, diuretic use, diabetes, or alcohol use, but it does not justify claiming that everyone needs high-dose magnesium for hearing protection.

For readers interested in nerve signaling more generally, our article on magnesium and nerve function explains why magnesium’s relationship to excitability is relevant across peripheral and central nervous-system biology. The key point for hearing is modest: normal magnesium physiology may matter to auditory tissues, while a clinical prevention claim requires direct trials with hearing endpoints.

Magnesium and Ototoxicity: Dose, Form, and Evidence Compared

No evidence-based magnesium dose has been established specifically to prevent ototoxicity. The doses below come from studies of sleep or mood-related outcomes, not hearing preservation. They should therefore be read as examples of researched magnesium exposure, not as protocols for patients receiving chemotherapy, intravenous antibiotics, or other potentially ototoxic treatment.

Study and population	Magnesium intervention	Measured outcome	What it means for hearing protection
Abbasi et al. (2012); 46 older adults with primary insomnia	500 mg/day for 8 weeks	Sleep and insomnia-related outcomes	Shows a controlled human supplementation study, but no audiometry, tinnitus, or ototoxicity endpoint
Tarleton et al. (2017); 126 adults with mild-to-moderate depression	248 mg/day elemental magnesium as magnesium chloride for 6 weeks	PHQ-9 and anxiety symptom scores	Supports neither prevention nor treatment of medication-related hearing loss
Boyle et al. (2017); systematic review of 18 studies	Varied formulations and protocols	Subjective anxiety and stress	Suggests heterogeneous evidence even outside hearing; direct ototoxicity evidence is absent

Magnesium form affects tolerability and the amount of elemental magnesium delivered, but “better absorbed” does not automatically mean “better for hearing.” Magnesium glycinate is commonly selected because it is generally well tolerated by many people, while magnesium chloride was the form used in Tarleton et al. (2017). The available studies do not compare glycinate with chloride, citrate, oxide, or other forms for cochlear protection, so no product form can be ranked for this specific purpose.

Timing is also unresolved. There is no human evidence in the supplied references showing that taking magnesium before an ototoxic drug, during treatment, or after exposure changes hearing outcomes. In contrast, clinical hearing surveillance has a clear rationale: it can identify threshold changes early, document baseline function, and inform the prescribing team. Anyone considering a supplement during active medical treatment should first ask whether kidney function, gastrointestinal symptoms, other medicines, and the treatment plan make supplementation appropriate.

Some people may choose a glycinate product for broader stress or nutritional support rather than for a hearing claim. PEPAX Magnesium Glycinate with Astragalus & B6 is formulated around that broader context, but it should not be presented as a treatment for ototoxicity or as a replacement for oncology, infectious-disease, or audiology care. Astragalus and vitamin B6 do not change the absence of direct magnesium-and-hearing-protection trials in the reference list.

Who May Benefit From Addressing Magnesium During Ototoxicity Risk

The people most likely to benefit from magnesium attention are those with a credible risk of low magnesium status, not a proven subgroup with medication-related hearing protection. This is a nutritional-risk framework, not an ototoxicity-treatment recommendation. The strongest direct evidence in the supplied literature concerns sleep and mood populations, while the hearing-specific evidence remains unknown.

Older adults are one reasonable group to consider because lower dietary intake, reduced absorption, medication use, and chronic disease can make inadequate magnesium intake more likely. Abbasi et al. (2012) specifically enrolled elderly participants with primary insomnia, illustrating that magnesium supplementation has been studied in this age group. Yet older age also increases the importance of medication review and kidney-function assessment, since impaired renal clearance can raise the risk of magnesium accumulation.

People using medications or living with conditions associated with magnesium loss may also warrant clinical assessment. DiNicolantonio et al. (2018) discusses the public-health implications of subclinical magnesium deficiency, while Gröber et al. (2015) reviews magnesium’s therapeutic and preventive relevance across multiple physiological systems. Examples worth discussing with a clinician include chronic gastrointestinal losses, restricted diets, substantial alcohol intake, diabetes, and use of some diuretics or acid-suppressing medicines. These are reasons to assess nutritional context; they are not evidence that supplementation prevents hearing damage.

Individuals under sustained stress may be interested in magnesium for reasons separate from auditory protection. Boyle et al. (2017) found suggestive but heterogeneous evidence for subjective anxiety and stress outcomes, and Tarleton et al. (2017) found improvement in depression symptoms in its specific study population. If stress, sleep disruption, and tinnitus coexist, it is important to separate symptom support from a claim that magnesium reverses inner-ear injury. Our overview of magnesium and tinnitus examines that distinction in more detail.

Patients receiving known ototoxic treatments deserve a higher standard of care than supplement self-experimentation. They may benefit from discussing baseline and follow-up audiology, new tinnitus, imbalance, muffled hearing, difficulty understanding speech, kidney function, and other drugs that could compound risk. Sudden hearing loss, one-sided hearing changes, severe vertigo, or rapidly worsening tinnitus should prompt urgent clinical evaluation rather than a trial of supplements.

Magnesium and Ototoxicity: Practical, Evidence-Based Takeaways

Practical decisions about magnesium and ototoxicity should prioritize diagnosis, nutritional adequacy, and medical monitoring over unproven prevention claims. The available research supports a cautious approach: correct a likely deficiency when clinically appropriate, but do not represent magnesium as established hearing protection.

• Do not rely on magnesium to prevent hearing loss from chemotherapy, aminoglycoside antibiotics, loop diuretics, or other ototoxic exposures; direct human evidence is not provided here.
• Ask the prescribing clinician whether baseline and follow-up hearing tests are appropriate when a medicine carries recognized auditory risk.
• Consider magnesium status in the context of diet, gastrointestinal loss, diabetes, alcohol use, and medicines that may affect magnesium balance; serum magnesium alone may not fully reflect total-body status.
• Use study doses accurately: Abbasi et al. (2012) used 500 mg/day in 46 older adults with insomnia, while Tarleton et al. (2017) used 248 mg/day elemental magnesium in 126 adults with depression; neither dose is validated for hearing protection.
• Choose a supplement form primarily for tolerability and clinician-guided nutritional needs, not because a particular form has been proven to protect cochlear hair cells.
• Report new ringing, hearing change, dizziness, or balance symptoms promptly. For the oxidative-stress aspect of hearing research, see our discussion of hydrogen water and inner-ear oxidative damage; it likewise requires careful separation of mechanism from clinical proof.

There is also a practical reason not to treat blood testing as the whole story. Magnesium is largely stored in bone and soft tissue, while serum concentrations are maintained within a narrow range. Our guide to magnesium deficiency and why blood tests can miss it explains why dietary history, symptoms, medicines, and clinical context may matter alongside laboratory values. That does not mean laboratory testing is useless; it means results should be interpreted by a clinician rather than used to justify indiscriminate high-dose supplementation.

Magnesium and Ototoxicity: The Bottom Line on Hearing Protection Evidence

Magnesium and ototoxicity are biologically connected by plausible mechanisms involving cellular energy, ion regulation, excitatory signaling, and oxidative stress, but plausible mechanisms are not clinical proof. The supplied human studies support limited conclusions about magnesium in insomnia and mood-related populations, not prevention of medication-induced hearing loss. Until well-designed trials measure audiometry and clinically meaningful auditory outcomes in at-risk patients, magnesium should be considered supportive nutrition when appropriate—not an evidence-established otoprotective therapy.

---

References

1. Abbasi B, et al. "The effect of magnesium supplementation on primary insomnia in elderly: A double-blind placebo-controlled clinical trial." Journal of Research in Medical Sciences. 2012;17(12):1161–1169. [Source]
2. Boyle NB, et al. "The Effects of Magnesium Supplementation on Subjective Anxiety and Stress — A Systematic Review." Nutrients. 2017;9(5):429. [Source]
3. Gröber U, et al. "Magnesium in Prevention and Therapy." Nutrients. 2015;7(9):8199–8226. [Source]
4. DiNicolantonio JJ, et al. "Subclinical magnesium deficiency: a principal driver of cardiovascular disease and a public health crisis." Open Heart. 2018;5(1):e000668. [Source]
5. Tarleton EK, et al. "Role of magnesium supplementation in the treatment of depression: A randomized clinical trial." PLOS ONE. 2017;12(6):e0180067. [Source]

---

---